Biorep Technologies Achieves Milestone with PRISM System for Islet Isolation
In a significant development for the field of cellular therapies, Biorep Technologies has announced the successful use of its innovative PRISM system for the isolation of human pancreatic islets. This achievement marks a pivotal moment as the first independent research implementation of the PRISM system, carried out at the Scottish National Blood Transfusion Service (SNBTS) in conjunction with Leiden University Medical Center (LUMC). Such collaborations are crucial as they showcase the capability of the PRISM system to deliver reproducible results across different laboratory settings.
Felipe Echeverri, CEO of Biorep Technologies, expressed optimism about the results, stating, "This milestone underscores Biorep's commitment to advancing the science of cell isolation through reliable laboratory technologies that make complex workflows consistent, accessible, and scalable." The successful execution of the PRISM system in an independent lab suggests that it may soon set a new international standard for islet and other cell isolation processes.
The urgency for such advancements has been heightened by the impending phase-out of established cell separators, such as the COBE 2991, which is expected to conclude by the end of 2025. Many laboratories are actively on the lookout for a modern, standardized platform to facilitate ongoing studies in islet isolation. The PRISM system offers a compelling solution, functioning as an automated, closed, and modular laboratory system capable of achieving reproducible islet isolations in controlled, sterile conditions. This not only lessens the dependence on operators but also reduces the necessary facility requirements, making it a robust alternative in research environments investigating islet purification and other cell isolation protocols.
The collaboration between LUMC, SNBTS, and Biorep is set to continue through an evaluation program, with results anticipated to be shared during EPITA 2026. Initial results of the system were previously reported by Doppenberg et al. in 2022, and this recent development builds upon those findings. Many in the field are considering the PRISM system among the most important advancements in islet isolation science over the last three decades.
Biorep Technologies, based in Miami, Florida, stands as a global leader in advanced cell and tissue isolation systems. With a commitment to supporting scientific progress in areas like diabetes treatment, cell therapy, and regenerative medicine, the company has spent over 30 years effectively merging engineering precision with biological insights. This dedication has allowed Biorep to deliver reliable and replicable solutions that fuel innovation in leading research centers globally.
The PRISM system itself, originally developed at LUMC and subsequently optimized by Biorep for large-scale deployment, is a closed-system platform designed for multiple functions including tissue collection, washing, buffer exchange, and islet purification. As an advancement in technology, the PRISM system aims to streamline and automate the isolation of allogeneic pancreatic islets, with additional applications for autologous islet and hepatocyte isolation currently in development.
For more information on Biorep Technologies and its pioneering systems, interested parties can visit their website at www.biorepdiabetes.com.
In summary, Biorep Technologies' announcement represents a landmark achievement in cellular therapy research and cell isolation technology, providing hope for future advancements and a potential standard for islet isolation across laboratories worldwide.
Felipe Echeverri, CEO of Biorep Technologies, expressed optimism about the results, stating, "This milestone underscores Biorep's commitment to advancing the science of cell isolation through reliable laboratory technologies that make complex workflows consistent, accessible, and scalable." The successful execution of the PRISM system in an independent lab suggests that it may soon set a new international standard for islet and other cell isolation processes.
The urgency for such advancements has been heightened by the impending phase-out of established cell separators, such as the COBE 2991, which is expected to conclude by the end of 2025. Many laboratories are actively on the lookout for a modern, standardized platform to facilitate ongoing studies in islet isolation. The PRISM system offers a compelling solution, functioning as an automated, closed, and modular laboratory system capable of achieving reproducible islet isolations in controlled, sterile conditions. This not only lessens the dependence on operators but also reduces the necessary facility requirements, making it a robust alternative in research environments investigating islet purification and other cell isolation protocols.
The collaboration between LUMC, SNBTS, and Biorep is set to continue through an evaluation program, with results anticipated to be shared during EPITA 2026. Initial results of the system were previously reported by Doppenberg et al. in 2022, and this recent development builds upon those findings. Many in the field are considering the PRISM system among the most important advancements in islet isolation science over the last three decades.
Biorep Technologies, based in Miami, Florida, stands as a global leader in advanced cell and tissue isolation systems. With a commitment to supporting scientific progress in areas like diabetes treatment, cell therapy, and regenerative medicine, the company has spent over 30 years effectively merging engineering precision with biological insights. This dedication has allowed Biorep to deliver reliable and replicable solutions that fuel innovation in leading research centers globally.
The PRISM system itself, originally developed at LUMC and subsequently optimized by Biorep for large-scale deployment, is a closed-system platform designed for multiple functions including tissue collection, washing, buffer exchange, and islet purification. As an advancement in technology, the PRISM system aims to streamline and automate the isolation of allogeneic pancreatic islets, with additional applications for autologous islet and hepatocyte isolation currently in development.
For more information on Biorep Technologies and its pioneering systems, interested parties can visit their website at www.biorepdiabetes.com.
In summary, Biorep Technologies' announcement represents a landmark achievement in cellular therapy research and cell isolation technology, providing hope for future advancements and a potential standard for islet isolation across laboratories worldwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.